Sarepta Therapeutics’ (SRPT) "Buy" Rating Reiterated at Robert W. Baird – MarketBeat

Sarepta Therapeutics (NASDAQ:SRPT)'s stock had its "buy" rating reaffirmed by investment analysts at Robert W. Baird in a report released on Friday, TipRanks reports. They currently have a $192.00 target price on the biotechnology company's stock. Robert W. Baird's target price suggests a potential upside of 35.93% from the company's previous close.

Other analysts also recently issued research reports about the stock. BidaskClub raised shares of Sarepta Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 7th. Nomura Securities reaffirmed a "buy" rating and set a $230.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, February 25th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $217.00 price objective (up previously from $211.00) on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Oppenheimer reissued a "hold" rating on shares of Sarepta Therapeutics in a research report on Thursday, May 7th. Finally, SVB Leerink reaffirmed a "buy" rating and set a $216.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twenty-four have given a buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $193.05.

Shares of NASDAQ SRPT opened at $141.25 on Friday. The stock has a fifty day moving average price of $112.04 and a 200 day moving average price of $112.85. The company has a market cap of $9.91 billion, a P/E ratio of -16.00 and a beta of 1.87. Sarepta Therapeutics has a 12-month low of $72.05 and a 12-month high of $158.80. The company has a current ratio of 8.31, a quick ratio of 7.75 and a debt-to-equity ratio of 0.66.

Hands down, the biggest profits in 2020 will go to investors who own these three stocks. Claim your free copy of my Breakthrough Stock special report...

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.17) by $1.94. The company had revenue of $113.67 million during the quarter, compared to the consensus estimate of $118.18 million. Sarepta Therapeutics had a negative return on equity of 64.67% and a negative net margin of 160.96%. The company's revenue was up 30.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.07) earnings per share. On average, sell-side analysts forecast that Sarepta Therapeutics will post -8.44 EPS for the current fiscal year.

In other news, Director Richard Barry sold 30,000 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $141.26, for a total transaction of $4,237,800.00. Following the completion of the transaction, the director now directly owns 3,163,813 shares of the company's stock, valued at $446,920,224.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $116.89, for a total value of $584,450.00. Following the sale, the director now owns 18,792 shares in the company, valued at $2,196,596.88. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of SRPT. Amundi Pioneer Asset Management Inc. increased its position in Sarepta Therapeutics by 32.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company's stock worth $18,428,000 after buying an additional 38,194 shares during the period. DNB Asset Management AS acquired a new position in shares of Sarepta Therapeutics during the fourth quarter valued at $1,386,000. Zeke Capital Advisors LLC grew its position in shares of Sarepta Therapeutics by 10.1% during the fourth quarter. Zeke Capital Advisors LLC now owns 5,343 shares of the biotechnology company's stock worth $689,000 after acquiring an additional 491 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter worth about $860,000. Finally, Janney Montgomery Scott LLC lifted its position in Sarepta Therapeutics by 7.7% in the 4th quarter. Janney Montgomery Scott LLC now owns 5,312 shares of the biotechnology company's stock valued at $685,000 after purchasing an additional 382 shares during the last quarter. Hedge funds and other institutional investors own 93.76% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: Federal Reserve

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected]

8 Stocks You Can Count On During Any Crisis

Depending on how you look at it, the economic outlook is getting cloudier or clearer.

The argument for a cloudy economy is easy to make. Multiple times of day we hear about more Americans testing positive for the novel coronavirus. The worldwide number of positive tests exceeds one million. And unfortunately, it will go higher. We just dont know by how much.

But there are two parts to this ongoing situation. The first is the real-time science experiment as the world attempts to flatten the curve. The other is the very real economic impact. And the numbers of the economic carnage are coming in faster than any significant evidence of a flattening curve.

The number of unemployed now exceeds six million and will only rise. The government is throwing everything including the kitchen sink at the problem. But its an experiment in real-time. We wont know the results for some time.

But even while we wait for a new normal to return, there are ways for you to profit. There are companies that are keeping our economy going now, and have a business model that sets them up well for success after the pandemic is over.

View the "8 Stocks You Can Count On During Any Crisis".

Follow this link:
Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Robert W. Baird - MarketBeat